日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting IL-7Rα with PNU-159682 antibody-drug conjugates in acute lymphoblastic leukemia: translational implications

利用 PNU-159682 抗体药物偶联物靶向 IL-7Rα 治疗急性淋巴细胞白血病:转化意义

Yang, Shiqi; Anzai, Takahiro; Tsumura, Ryo; Fuchigami, Hirobumi; Hamada, Motochika; Yuda, Junichiro; Ikuta, Koichi; Yasunaga, Masahiro

Attenuated Toxicity and Antitoxic Mechanism via Sodium Iodide Symporter Inhibition-Based Tumor-Selective Delivery in Astatine-211 Radioimmunotherapy

通过基于钠碘转运蛋白抑制的肿瘤选择性递送,降低砹-211放射免疫疗法的毒性并发挥抗毒机制

Takashima, Hiroki; Tsumura, Ryo; Koga, Yoshikatsu; Anzai, Takahiro; Yin, Xiaojie; Sato, Nozomi; Shigekawa, Yudai; Kanayama, Yousuke; Nambu, Akihiro; Usuda, Sachiko; Haba, Hiromitsu; Sakashita, Shingo; Inaki, Anri; Manabe, Shino; Yasunaga, Masahiro

Immunological synapse formation as a key mechanism in T cell-dependent bispecific antibody-mediated immune activation and cytotoxicity.

免疫突触形成是 T 细胞依赖性双特异性抗体介导的免疫激活和细胞毒性的关键机制

Nakamura Rikuto, Tsumura Ryo, Anzai Takahiro, Asano Ryutaro, Yasunaga Masahiro

Anti-tissue factor antibody conjugated with monomethyl auristatin E or deruxtecan in pancreatic cancer models

在胰腺癌模型中,抗组织因子抗体与单甲基澳瑞他汀E或德鲁替康偶联

Tsumura, Ryo; Anzai, Takahiro; Koga, Yoshikatsu; Takashima, Hiroki; Matsumura, Yasuhiro; Yasunaga, Masahiro

Bispecific Antibodies Produced via Chemical Site-Specific Conjugation Technology: AJICAP Second-Generation

通过化学位点特异性偶联技术生产的双特异性抗体:AJICAP 第二代

Fujii, Tomohiro; Ito, Kenichiro; Takahashi, Kazutoshi; Aoki, Tsubasa; Takasugi, Rika; Seki, Takuya; Iwai, Yusuke; Watanabe, Tomohiro; Hirama, Ryusuke; Tsumura, Ryo; Fuchigami, Hirobumi; Yasunaga, Masahiro; Matsuda, Yutaka

Expansion of mixed immune cells using CD3/CD161 co-stimulation for the treatment of cancer

利用CD3/CD161共刺激扩增混合免疫细胞治疗癌症

Tsumura, Ryo; Haruta, Miwa; Kuwano, Masataka; Yasunaga, Masahiro

Assessing the Correlation Between Visual Acuity and Critical Fusion Frequency in Acute Optic Neuritis Before and After Steroid Therapy

评估急性视神经炎患者在类固醇治疗前后视力与临界融合频率的相关性

Tsumura, Ryo; Harada, Yosuke; Chuman, Hideki; Kiuchi, Yoshiaki

Radioimmunotherapy with an (211) At-labeled anti-tissue factor antibody protected by sodium ascorbate

使用抗坏血酸钠保护的(211)At标记的抗组织因子抗体进行放射免疫治疗

Takashima, Hiroki; Koga, Yoshikatsu; Manabe, Shino; Ohnuki, Kazunobu; Tsumura, Ryo; Anzai, Takahiro; Iwata, Nozomi; Wang, Yang; Yokokita, Takuya; Komori, Yukiko; Mori, Daiki; Usuda, Sachiko; Haba, Hiromitsu; Fujii, Hirofumi; Matsumura, Yasuhiro; Yasunaga, Masahiro

High expression of TMEM180, a novel tumour marker, is associated with poor survival in stage III colorectal cancer

TMEM180是一种新型肿瘤标志物,其高表达与III期结直肠癌患者的预后不良相关。

Shiraishi, Takuya; Ikeda, Koji; Tsukada, Yuichiro; Nishizawa, Yuji; Sasaki, Takeshi; Ito, Masaaki; Kojima, Motohiro; Ishii, Genichiro; Tsumura, Ryo; Saijou, Sinji; Koga, Yoshikatsu; Yasunaga, Masahiro; Matsumura, Yasuhiro

Report of the use of patient-derived xenograft models in the development of anticancer drugs in Japan

日本利用患者来源异种移植模型开发抗癌药物的报告

Tsumura, Ryo; Koga, Yoshikatsu; Hamada, Akinobu; Kuwata, Takeshi; Sasaki, Hiroki; Doi, Toshihiko; Aikawa, Katsuji; Ohashi, Akihiro; Katano, Ikumi; Ikarashi, Yoshinori; Ito, Mamoru; Ochiai, Atsushi